About Abiomed

Abiomed® (NASDAQ: ABMD) is a pioneer and global leader in healthcare technology and innovation, focused on breaking new ground in RECOVERING HEARTS AND SAVING LIVES. Because hundreds of people die each year waiting for heart transplants, Abiomed CEO, Chairman and President, Michael R. Minogue has focused the company’s efforts on developing ground-breaking heart muscle recovery technologies designed to assist or replace the life-sustaining pumping function of the failing heart.

The Company’s portfolio of heart recovery products and services offer healthcare professionals an array of choices across a broad clinical spectrum. Abiomed’s minimally invasive devices enable the heart to rest, heal and recover by improving blood flow and circulatory support.  Through the use of Abiomed’s heart recovery products, patients can return home to live longer and fuller lives with their own native heart.

From the world’s first total replacement heart to a catheter-based device that provides circulatory support with rapid and simple insertion, Abiomed is dedicated to finding ways to treat heart failure so that patients and physicians have the most advanced, successful, and beneficial technology available to improve quality of life.

« back to top

Quick Facts

Company founded in 1981
Corporate Headquarters: Danvers, Massachusetts
European Division: Aachen, Germany
Number of Employees: 400+
NASDAQ Symbol: ABMD
Only company with FDA approval for heart recovery
First and only World’s Smallest Heart Pump
First Total Artificial Heart
Impella is "changing how everybody is practicing."

“It’s making this product available for everybody who does, increase the complexity of the cases they do and with the Abiomed support team available, it’s changing how everybody is practicing”

Richard Shlofmitz – St. Francis Hospital, Roslyn, NY